Efficacy and Safety Study of Benralizumab Added to Medium-dose Inhaled Corticosteroid Plus LABA in Patients With Uncontrolled Asthma

NCT01947946 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

13

Enrollment

INDUSTRY

Sponsor class

Stopped Study terminated due to sponsor decision

Conditions

Asthma

Interventions

BIOLOGICAL: Benralizumab
BIOLOGICAL: Placebo

Sponsor

AstraZeneca